

# **Compounding Chemotherapy Market By Dose type (Chemotherapeutic, Non-chemotherapeutic), By Compounding Type (Pharmaceutical Ingredient Alteration, Currently Unavailable Pharmaceutical Manufacturing, Pharmaceutical Dosage Alteration), By Delivery method (Gravimetric automated Compounding Device, Volumetric Automated Compounding Device), By Sterility (Sterile, Non-sterile), By Technology (With Robotic arm, Without Robotic Arm): Global Opportunity Analysis and Industry Forecast, 2025-2034**

<https://marketpublishers.com/r/C26263A8F3A6EN.html>

Date: April 2025

Pages: 364

Price: US\$ 2,655.00 (Single User License)

ID: C26263A8F3A6EN

## **Abstracts**

The compounding chemotherapy market was valued at \$5,267.03 million in 2024 and is estimated to reach \$9,826.7 million by 2034, exhibiting a CAGR of 6.4% from 2025 to 2034. Compounding chemotherapy involves the specialized preparation of customized chemotherapy medications by trained pharmacists, typically in a compounding or hospital pharmacy. This process includes the precise mixing, modifying, or combining of chemotherapy drugs to address the specific needs of individual patients.

Compounded formulations are often necessary when commercial products are unavailable, when a tailored dosage or drug combination is required, or when patients have allergies to ingredients in standard treatments. By combining drugs with different mechanisms of action, compounded chemotherapy can target cancer cells at various stages of their growth cycle, potentially improving therapeutic outcomes.

The compounding chemotherapy market is experiencing robust growth, driven by a rising global cancer burden, increasing demand for personalized medicine, and the need for customized drug formulations. According to the World Health Organization (WHO), over 35 million new cancer cases are projected by 2050—representing a 77% increase from the 20 million cases reported in 2022. This surge has significantly heightened the demand for comprehensive and effective cancer treatments, contributing to the growing adoption of compounded chemotherapy.

Compounding chemotherapy, which typically involves combining two or more chemotherapeutic agents, is increasingly favored for its synergistic effects in targeting cancer cells, reducing drug resistance, and improving clinical outcomes. The expansion of personalized medicine and advancements in genomics have further supported the development of individualized treatment regimens based on specific tumor profiles, bolstering market demand.

Another key market driver is the increasing investment in research and development by pharmaceutical companies and academic institutions, aimed at creating novel compound formulations with enhanced safety and efficacy. Regulatory bodies are also contributing to market growth by offering fast-track approvals and incentives for innovative and breakthrough therapies.

Growing awareness among healthcare professionals and patients regarding the advantages of combination therapies—along with improved diagnostic technologies—has accelerated market penetration, particularly in developed regions such as North America and Europe. Additionally, the expansion of compounding chemotherapy in pediatric oncology and the emergence of outpatient and home-based cancer treatment options are creating new growth opportunities, particularly for compact and user-friendly compounding systems.

However, clinical challenges remain. The risk of cumulative toxicity and potential drug interactions necessitates close patient monitoring and individualized dosage adjustments, which can limit broader adoption.

Key players operating in the market have adopted product launch, acquisition, and partnership as their key strategies to expand their product portfolio. For example, the SmartCompounders robotic chemo-automation system by Simplivia is engineered to enhance the safety, accuracy, and efficiency of cytotoxic drug preparation. A standout feature of this system is its precision-driven gravimetric control, which employs ten distinct load cells to measure medication dosing in real time post-injection, ensuring

total accuracy and reliability. This gravimetric approach minimizes dosing errors and enhances patient safety.

### **Segment Review:**

The compounding chemotherapy market is segmented into dose type, compounding type, delivery method, sterility, technology, and region. By dose type, the market is segregated into chemotherapeutic and non-chemotherapeutic. By compounding type, the market is classified into pharmaceutical ingredient alteration, currently unavailable pharmaceutical manufacturing, and pharmaceutical dosage alteration. By delivery method, the market is segmented into gravimetric automated compounding devices, and volumetric automated compounding devices. By sterility, the market is segmented into sterile and non-sterile. By technology, the market is segmented into with robotic arm and without robotic arm. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Major key players that operate in the global compounding chemotherapy market are ATS Corporation, Grifols, S.A., EQUASHIELD, Dedalus S.p.A., ARXIUM, Omnicell Inc., Kapsam Health Products, Simplivia, Biovalley Group S.p.A., and Loccioni.

### **Key Benefits for Stakeholders**

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the compounding chemotherapy market analysis from 2024 to 2034 to identify the prevailing compounding chemotherapy market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the compounding chemotherapy market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global compounding chemotherapy market trends, key players, market segments, application areas, and market growth strategies.

**Additional benefits you will get with this purchase are:**

Quarterly Update and\* (only available with a corporate license, on listed price)

5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

Free Upcoming Version on the Purchase of Five and Enterprise User License.

16 analyst hours of support\* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

15% Free Customization\* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

Free data Pack on the Five and Enterprise User License. (Excel version of the report)

Free Updated report if the report is 6-12 months old or older.

24-hour priority response\*

Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines

Additional company profiles with specific to client's interest

Average Selling Price Analysis / Price Point Analysis

Expanded list for Company Profiles

Historic market data

## **Key Market Segments**

### By Technology

With Robotic arm

Without Robotic Arm

### By Dose type

Non-chemotherapeutic

Chemotherapeutic

### By Compounding Type

Pharmaceutical Ingredient Alteration

Currently Unavailable Pharmaceutical Manufacturing

Pharmaceutical Dosage Alteration

### By Delivery method

Gravimetric automated Compounding Device

## Volumetric Automated Compounding Device

### By Sterility

Sterile

Non-sterile

### By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia-Pacific

Japan

China

India

Australia

South Korea

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

Key Market Players

Grifols, S.A.

EQUASHIELD

ARxIUM

Omnicell Inc.

Kapsam Health Products

Biovalley Group S.p.A.

Loccioni

ATS Corporation

Dedalus S.p.A.

Simplivia

## Contents

### **CHAPTER 1: INTRODUCTION**

- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
  - 1.4.1. Primary research
  - 1.4.2. Secondary research
  - 1.4.3. Analyst tools and models

### **CHAPTER 2: EXECUTIVE SUMMARY**

- 2.1. CXO perspective

### **CHAPTER 3: MARKET OVERVIEW**

- 3.1. Market definition and scope
- 3.2. Key findings
  - 3.2.1. Top impacting factors
  - 3.2.2. Top investment pockets
- 3.3. Porter's five forces analysis
  - 3.3.1. Moderate bargaining power of suppliers
  - 3.3.2. Moderate threat of new entrants
  - 3.3.3. Moderate threat of substitutes
  - 3.3.4. Moderate intensity of rivalry
  - 3.3.5. Low bargaining power of buyers
- 3.4. Market dynamics
  - 3.4.1. Drivers
    - 3.4.1.1. Rise in global cancer incidence
    - 3.4.1.2. Shortage of commercially available chemotherapy drugs
    - 3.4.1.3. The shift toward personalized medicine
  - 3.4.2. Restraints
    - 3.4.2.1. Shortage of trained personnel
  - 3.4.3. Opportunities
    - 3.4.3.1. Advancements in compounding technologies

### **CHAPTER 4: COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE**

*Compounding Chemotherapy Market By Dose type (Chemotherapeutic, Non-chemotherapeutic), By Compounding Type (Ph...*

#### 4.1. Overview

##### 4.1.1. Market size and forecast

#### 4.2. Chemotherapeutic

##### 4.2.1. Key market trends, growth factors and opportunities

##### 4.2.2. Market size and forecast, by region

##### 4.2.3. Market share analysis by country

#### 4.3. Non-chemotherapeutic

##### 4.3.1. Key market trends, growth factors and opportunities

##### 4.3.2. Market size and forecast, by region

##### 4.3.3. Market share analysis by country

### **CHAPTER 5: COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE**

#### 5.1. Overview

##### 5.1.1. Market size and forecast

#### 5.2. Pharmaceutical Ingredient Alteration

##### 5.2.1. Key market trends, growth factors and opportunities

##### 5.2.2. Market size and forecast, by region

##### 5.2.3. Market share analysis by country

#### 5.3. Currently Unavailable Pharmaceutical Manufacturing

##### 5.3.1. Key market trends, growth factors and opportunities

##### 5.3.2. Market size and forecast, by region

##### 5.3.3. Market share analysis by country

#### 5.4. Pharmaceutical Dosage Alteration

##### 5.4.1. Key market trends, growth factors and opportunities

##### 5.4.2. Market size and forecast, by region

##### 5.4.3. Market share analysis by country

### **CHAPTER 6: COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD**

#### 6.1. Overview

##### 6.1.1. Market size and forecast

#### 6.2. Gravimetric automated Compounding Device

##### 6.2.1. Key market trends, growth factors and opportunities

##### 6.2.2. Market size and forecast, by region

##### 6.2.3. Market share analysis by country

### 6.3. Volumetric Automated Compounding Device

- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country

## **CHAPTER 7: COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY**

### 7.1. Overview

- 7.1.1. Market size and forecast

### 7.2. Sterile

- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by region
- 7.2.3. Market share analysis by country

### 7.3. Non-sterile

- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by region
- 7.3.3. Market share analysis by country

## **CHAPTER 8: COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY**

### 8.1. Overview

- 8.1.1. Market size and forecast

### 8.2. With Robotic arm

- 8.2.1. Key market trends, growth factors and opportunities
- 8.2.2. Market size and forecast, by region
- 8.2.3. Market share analysis by country

### 8.3. Without Robotic Arm

- 8.3.1. Key market trends, growth factors and opportunities
- 8.3.2. Market size and forecast, by region
- 8.3.3. Market share analysis by country

## **CHAPTER 9: COMPOUNDING CHEMOTHERAPY MARKET, BY REGION**

### 9.1. Overview

- 9.1.1. Market size and forecast By Region

### 9.2. North America

- 9.2.1. Key market trends, growth factors and opportunities
- 9.2.2. Market size and forecast, by Dose type
- 9.2.3. Market size and forecast, by Compounding Type

- 9.2.4. Market size and forecast, by Delivery method
- 9.2.5. Market size and forecast, by Sterility
- 9.2.6. Market size and forecast, by Technology
- 9.2.7. Market size and forecast, by country
  - 9.2.7.1. U.S.
    - 9.2.7.1.1. Market size and forecast, by Dose type
    - 9.2.7.1.2. Market size and forecast, by Compounding Type
    - 9.2.7.1.3. Market size and forecast, by Delivery method
    - 9.2.7.1.4. Market size and forecast, by Sterility
    - 9.2.7.1.5. Market size and forecast, by Technology
  - 9.2.7.2. Canada
    - 9.2.7.2.1. Market size and forecast, by Dose type
    - 9.2.7.2.2. Market size and forecast, by Compounding Type
    - 9.2.7.2.3. Market size and forecast, by Delivery method
    - 9.2.7.2.4. Market size and forecast, by Sterility
    - 9.2.7.2.5. Market size and forecast, by Technology
  - 9.2.7.3. Mexico
    - 9.2.7.3.1. Market size and forecast, by Dose type
    - 9.2.7.3.2. Market size and forecast, by Compounding Type
    - 9.2.7.3.3. Market size and forecast, by Delivery method
    - 9.2.7.3.4. Market size and forecast, by Sterility
    - 9.2.7.3.5. Market size and forecast, by Technology
- 9.3. Europe
  - 9.3.1. Key market trends, growth factors and opportunities
  - 9.3.2. Market size and forecast, by Dose type
  - 9.3.3. Market size and forecast, by Compounding Type
  - 9.3.4. Market size and forecast, by Delivery method
  - 9.3.5. Market size and forecast, by Sterility
  - 9.3.6. Market size and forecast, by Technology
  - 9.3.7. Market size and forecast, by country
    - 9.3.7.1. Germany
      - 9.3.7.1.1. Market size and forecast, by Dose type
      - 9.3.7.1.2. Market size and forecast, by Compounding Type
      - 9.3.7.1.3. Market size and forecast, by Delivery method
      - 9.3.7.1.4. Market size and forecast, by Sterility
      - 9.3.7.1.5. Market size and forecast, by Technology
    - 9.3.7.2. France
      - 9.3.7.2.1. Market size and forecast, by Dose type
      - 9.3.7.2.2. Market size and forecast, by Compounding Type

9.3.7.2.3. Market size and forecast, by Delivery method

9.3.7.2.4. Market size and forecast, by Sterility

9.3.7.2.5. Market size and forecast, by Technology

#### 9.3.7.3. UK

9.3.7.3.1. Market size and forecast, by Dose type

9.3.7.3.2. Market size and forecast, by Compounding Type

9.3.7.3.3. Market size and forecast, by Delivery method

9.3.7.3.4. Market size and forecast, by Sterility

9.3.7.3.5. Market size and forecast, by Technology

#### 9.3.7.4. Italy

9.3.7.4.1. Market size and forecast, by Dose type

9.3.7.4.2. Market size and forecast, by Compounding Type

9.3.7.4.3. Market size and forecast, by Delivery method

9.3.7.4.4. Market size and forecast, by Sterility

9.3.7.4.5. Market size and forecast, by Technology

#### 9.3.7.5. Spain

9.3.7.5.1. Market size and forecast, by Dose type

9.3.7.5.2. Market size and forecast, by Compounding Type

9.3.7.5.3. Market size and forecast, by Delivery method

9.3.7.5.4. Market size and forecast, by Sterility

9.3.7.5.5. Market size and forecast, by Technology

#### 9.3.7.6. Rest of Europe

9.3.7.6.1. Market size and forecast, by Dose type

9.3.7.6.2. Market size and forecast, by Compounding Type

9.3.7.6.3. Market size and forecast, by Delivery method

9.3.7.6.4. Market size and forecast, by Sterility

9.3.7.6.5. Market size and forecast, by Technology

### 9.4. Asia-Pacific

9.4.1. Key market trends, growth factors and opportunities

9.4.2. Market size and forecast, by Dose type

9.4.3. Market size and forecast, by Compounding Type

9.4.4. Market size and forecast, by Delivery method

9.4.5. Market size and forecast, by Sterility

9.4.6. Market size and forecast, by Technology

9.4.7. Market size and forecast, by country

#### 9.4.7.1. Japan

9.4.7.1.1. Market size and forecast, by Dose type

9.4.7.1.2. Market size and forecast, by Compounding Type

9.4.7.1.3. Market size and forecast, by Delivery method

- 9.4.7.1.4. Market size and forecast, by Sterility
- 9.4.7.1.5. Market size and forecast, by Technology
- 9.4.7.2. China
  - 9.4.7.2.1. Market size and forecast, by Dose type
  - 9.4.7.2.2. Market size and forecast, by Compounding Type
  - 9.4.7.2.3. Market size and forecast, by Delivery method
  - 9.4.7.2.4. Market size and forecast, by Sterility
  - 9.4.7.2.5. Market size and forecast, by Technology
- 9.4.7.3. India
  - 9.4.7.3.1. Market size and forecast, by Dose type
  - 9.4.7.3.2. Market size and forecast, by Compounding Type
  - 9.4.7.3.3. Market size and forecast, by Delivery method
  - 9.4.7.3.4. Market size and forecast, by Sterility
  - 9.4.7.3.5. Market size and forecast, by Technology
- 9.4.7.4. Australia
  - 9.4.7.4.1. Market size and forecast, by Dose type
  - 9.4.7.4.2. Market size and forecast, by Compounding Type
  - 9.4.7.4.3. Market size and forecast, by Delivery method
  - 9.4.7.4.4. Market size and forecast, by Sterility
  - 9.4.7.4.5. Market size and forecast, by Technology
- 9.4.7.5. South Korea
  - 9.4.7.5.1. Market size and forecast, by Dose type
  - 9.4.7.5.2. Market size and forecast, by Compounding Type
  - 9.4.7.5.3. Market size and forecast, by Delivery method
  - 9.4.7.5.4. Market size and forecast, by Sterility
  - 9.4.7.5.5. Market size and forecast, by Technology
- 9.4.7.6. Rest of Asia-Pacific
  - 9.4.7.6.1. Market size and forecast, by Dose type
  - 9.4.7.6.2. Market size and forecast, by Compounding Type
  - 9.4.7.6.3. Market size and forecast, by Delivery method
  - 9.4.7.6.4. Market size and forecast, by Sterility
  - 9.4.7.6.5. Market size and forecast, by Technology
- 9.5. LAMEA
  - 9.5.1. Key market trends, growth factors and opportunities
  - 9.5.2. Market size and forecast, by Dose type
  - 9.5.3. Market size and forecast, by Compounding Type
  - 9.5.4. Market size and forecast, by Delivery method
  - 9.5.5. Market size and forecast, by Sterility
  - 9.5.6. Market size and forecast, by Technology

## 9.5.7. Market size and forecast, by country

### 9.5.7.1. Brazil

- 9.5.7.1.1. Market size and forecast, by Dose type
- 9.5.7.1.2. Market size and forecast, by Compounding Type
- 9.5.7.1.3. Market size and forecast, by Delivery method
- 9.5.7.1.4. Market size and forecast, by Sterility
- 9.5.7.1.5. Market size and forecast, by Technology

### 9.5.7.2. Saudi Arabia

- 9.5.7.2.1. Market size and forecast, by Dose type
- 9.5.7.2.2. Market size and forecast, by Compounding Type
- 9.5.7.2.3. Market size and forecast, by Delivery method
- 9.5.7.2.4. Market size and forecast, by Sterility
- 9.5.7.2.5. Market size and forecast, by Technology

### 9.5.7.3. South Africa

- 9.5.7.3.1. Market size and forecast, by Dose type
- 9.5.7.3.2. Market size and forecast, by Compounding Type
- 9.5.7.3.3. Market size and forecast, by Delivery method
- 9.5.7.3.4. Market size and forecast, by Sterility
- 9.5.7.3.5. Market size and forecast, by Technology

### 9.5.7.4. Rest of LAMEA

- 9.5.7.4.1. Market size and forecast, by Dose type
- 9.5.7.4.2. Market size and forecast, by Compounding Type
- 9.5.7.4.3. Market size and forecast, by Delivery method
- 9.5.7.4.4. Market size and forecast, by Sterility
- 9.5.7.4.5. Market size and forecast, by Technology

## **CHAPTER 10: COMPETITIVE LANDSCAPE**

- 10.1. Introduction
- 10.2. Top winning strategies
- 10.3. Product mapping of top 10 player
- 10.4. Competitive dashboard
- 10.5. Competitive heatmap
- 10.6. Top player positioning, 2024

## **CHAPTER 11: COMPANY PROFILES**

- 11.1. ATS Corporation
  - 11.1.1. Company overview

- 11.1.2. Key executives
- 11.1.3. Company snapshot
- 11.1.4. Operating business segments
- 11.1.5. Product portfolio
- 11.1.6. Business performance
- 11.2. Simplivia
  - 11.2.1. Company overview
  - 11.2.2. Key executives
  - 11.2.3. Company snapshot
  - 11.2.4. Operating business segments
  - 11.2.5. Product portfolio
  - 11.2.6. Key strategic moves and developments
- 11.3. Dedalus S.p.A.
  - 11.3.1. Company overview
  - 11.3.2. Key executives
  - 11.3.3. Company snapshot
  - 11.3.4. Operating business segments
  - 11.3.5. Product portfolio
  - 11.3.6. Key strategic moves and developments
- 11.4. EQUASHIELD
  - 11.4.1. Company overview
  - 11.4.2. Key executives
  - 11.4.3. Company snapshot
  - 11.4.4. Operating business segments
  - 11.4.5. Product portfolio
  - 11.4.6. Key strategic moves and developments
- 11.5. ARXIUM
  - 11.5.1. Company overview
  - 11.5.2. Key executives
  - 11.5.3. Company snapshot
  - 11.5.4. Operating business segments
  - 11.5.5. Product portfolio
- 11.6. Grifols, S.A.
  - 11.6.1. Company overview
  - 11.6.2. Key executives
  - 11.6.3. Company snapshot
  - 11.6.4. Operating business segments
  - 11.6.5. Product portfolio
  - 11.6.6. Business performance

- 11.7. Biovalley Group S.p.A.
  - 11.7.1. Company overview
  - 11.7.2. Key executives
  - 11.7.3. Company snapshot
  - 11.7.4. Operating business segments
  - 11.7.5. Product portfolio
- 11.8. Omnicell Inc.
  - 11.8.1. Company overview
  - 11.8.2. Key executives
  - 11.8.3. Company snapshot
  - 11.8.4. Operating business segments
  - 11.8.5. Product portfolio
  - 11.8.6. Business performance
  - 11.8.7. Key strategic moves and developments
- 11.9. Kapsam Health Products
  - 11.9.1. Company overview
  - 11.9.2. Key executives
  - 11.9.3. Company snapshot
  - 11.9.4. Operating business segments
  - 11.9.5. Product portfolio
- 11.10. Loccioni
  - 11.10.1. Company overview
  - 11.10.2. Key executives
  - 11.10.3. Company snapshot
  - 11.10.4. Operating business segments
  - 11.10.5. Product portfolio

## List Of Tables

### LIST OF TABLES

TABLE 01. GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 02. COMPOUNDING CHEMOTHERAPY MARKET FOR CHEMOTHERAPEUTIC, BY REGION, 2024-2034 (\$MILLION)

TABLE 03. COMPOUNDING CHEMOTHERAPY MARKET FOR NON-CHEMOTHERAPEUTIC, BY REGION, 2024-2034 (\$MILLION)

TABLE 04. GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 05. COMPOUNDING CHEMOTHERAPY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY REGION, 2024-2034 (\$MILLION)

TABLE 06. COMPOUNDING CHEMOTHERAPY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY REGION, 2024-2034 (\$MILLION)

TABLE 07. COMPOUNDING CHEMOTHERAPY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY REGION, 2024-2034 (\$MILLION)

TABLE 08. GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 09. COMPOUNDING CHEMOTHERAPY MARKET FOR GRAVIMETRIC AUTOMATED COMPOUNDING DEVICE, BY REGION, 2024-2034 (\$MILLION)

TABLE 10. COMPOUNDING CHEMOTHERAPY MARKET FOR VOLUMETRIC AUTOMATED COMPOUNDING DEVICE, BY REGION, 2024-2034 (\$MILLION)

TABLE 11. GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 12. COMPOUNDING CHEMOTHERAPY MARKET FOR STERILE, BY REGION, 2024-2034 (\$MILLION)

TABLE 13. COMPOUNDING CHEMOTHERAPY MARKET FOR NON-STERILE, BY REGION, 2024-2034 (\$MILLION)

TABLE 14. GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 15. COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARM, BY REGION, 2024-2034 (\$MILLION)

TABLE 16. COMPOUNDING CHEMOTHERAPY MARKET FOR WITHOUT ROBOTIC ARM, BY REGION, 2024-2034 (\$MILLION)

TABLE 17. COMPOUNDING CHEMOTHERAPY MARKET, BY REGION, 2024-2034 (\$MILLION)

TABLE 18. NORTH AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY

DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 19. NORTH AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 20. NORTH AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 21. NORTH AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 22. NORTH AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 23. NORTH AMERICA COMPOUNDING CHEMOTHERAPY MARKET, BY COUNTRY, 2024-2034 (\$MILLION)

TABLE 24. U.S. COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 25. U.S. COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 26. U.S. COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 27. U.S. COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 28. U.S. COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 29. CANADA COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 30. CANADA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 31. CANADA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 32. CANADA COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 33. CANADA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 34. MEXICO COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 35. MEXICO COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 36. MEXICO COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 37. MEXICO COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 38. MEXICO COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 39. EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 40. EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 41. EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 42. EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 43. EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 44. EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY COUNTRY, 2024-2034 (\$MILLION)

TABLE 45. GERMANY COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 46. GERMANY COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 47. GERMANY COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 48. GERMANY COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 49. GERMANY COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 50. FRANCE COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 51. FRANCE COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 52. FRANCE COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 53. FRANCE COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 54. FRANCE COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 55. UK COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 56. UK COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 57. UK COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY

METHOD, 2024-2034 (\$MILLION)

TABLE 58. UK COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 59. UK COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 60. ITALY COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 61. ITALY COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 62. ITALY COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 63. ITALY COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 64. ITALY COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 65. SPAIN COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 66. SPAIN COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 67. SPAIN COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 68. SPAIN COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 69. SPAIN COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 70. REST OF EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 71. REST OF EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 72. REST OF EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 73. REST OF EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 74. REST OF EUROPE COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 75. ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 76. ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 77. ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 78. ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 79. ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 80. ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY COUNTRY, 2024-2034 (\$MILLION)

TABLE 81. JAPAN COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 82. JAPAN COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 83. JAPAN COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 84. JAPAN COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 85. JAPAN COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 86. CHINA COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 87. CHINA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 88. CHINA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 89. CHINA COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 90. CHINA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 91. INDIA COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 92. INDIA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 93. INDIA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 94. INDIA COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 95. INDIA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 96. AUSTRALIA COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE

TYPE, 2024-2034 (\$MILLION)

TABLE 97. AUSTRALIA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 98. AUSTRALIA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 99. AUSTRALIA COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 100. AUSTRALIA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 101. SOUTH KOREA COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 102. SOUTH KOREA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 103. SOUTH KOREA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 104. SOUTH KOREA COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 105. SOUTH KOREA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 106. REST OF ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 107. REST OF ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 108. REST OF ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 109. REST OF ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 110. REST OF ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 111. LAMEA COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 112. LAMEA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 113. LAMEA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 114. LAMEA COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 115. LAMEA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 116. LAMEA COMPOUNDING CHEMOTHERAPY MARKET, BY COUNTRY, 2024-2034 (\$MILLION)

TABLE 117. BRAZIL COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 118. BRAZIL COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 119. BRAZIL COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 120. BRAZIL COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 121. BRAZIL COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 122. SAUDI ARABIA COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 123. SAUDI ARABIA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 124. SAUDI ARABIA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 125. SAUDI ARABIA COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 126. SAUDI ARABIA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 127. SOUTH AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 128. SOUTH AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 129. SOUTH AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 130. SOUTH AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024-2034 (\$MILLION)

TABLE 131. SOUTH AFRICA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 132. REST OF LAMEA COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024-2034 (\$MILLION)

TABLE 133. REST OF LAMEA COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024-2034 (\$MILLION)

TABLE 134. REST OF LAMEA COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024-2034 (\$MILLION)

TABLE 135. REST OF LAMEA COMPOUNDING CHEMOTHERAPY MARKET, BY

STERILITY, 2024-2034 (\$MILLION)

TABLE 136. REST OF LAMEA COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024-2034 (\$MILLION)

TABLE 137. ATS CORPORATION: KEY EXECUTIVES

TABLE 138. ATS CORPORATION: COMPANY SNAPSHOT

TABLE 139. ATS CORPORATION: PRODUCT SEGMENTS

TABLE 140. ATS CORPORATION: PRODUCT PORTFOLIO

TABLE 141. SIMPLIVIA: KEY EXECUTIVES

TABLE 142. SIMPLIVIA: COMPANY SNAPSHOT

TABLE 143. SIMPLIVIA: PRODUCT SEGMENTS

TABLE 144. SIMPLIVIA: PRODUCT PORTFOLIO

TABLE 145. SIMPLIVIA: KEY STRATERGIES

TABLE 146. DEDALUS S.P.A.: KEY EXECUTIVES

TABLE 147. DEDALUS S.P.A.: COMPANY SNAPSHOT

TABLE 148. DEDALUS S.P.A.: PRODUCT SEGMENTS

TABLE 149. DEDALUS S.P.A.: PRODUCT PORTFOLIO

TABLE 150. DEDALUS S.P.A.: KEY STRATERGIES

TABLE 151. EQUASHIELD: KEY EXECUTIVES

TABLE 152. EQUASHIELD: COMPANY SNAPSHOT

TABLE 153. EQUASHIELD: PRODUCT SEGMENTS

TABLE 154. EQUASHIELD: PRODUCT PORTFOLIO

TABLE 155. EQUASHIELD: KEY STRATERGIES

TABLE 156. ARXIUM: KEY EXECUTIVES

TABLE 157. ARXIUM: COMPANY SNAPSHOT

TABLE 158. ARXIUM: PRODUCT SEGMENTS

TABLE 159. ARXIUM: PRODUCT PORTFOLIO

TABLE 160. GRIFOLS, S.A.: KEY EXECUTIVES

TABLE 161. GRIFOLS, S.A.: COMPANY SNAPSHOT

TABLE 162. GRIFOLS, S.A.: PRODUCT SEGMENTS

TABLE 163. GRIFOLS, S.A.: PRODUCT PORTFOLIO

TABLE 164. BIOVALLEY GROUP S.P.A.: KEY EXECUTIVES

TABLE 165. BIOVALLEY GROUP S.P.A.: COMPANY SNAPSHOT

TABLE 166. BIOVALLEY GROUP S.P.A.: PRODUCT SEGMENTS

TABLE 167. BIOVALLEY GROUP S.P.A.: PRODUCT PORTFOLIO

TABLE 168. OMNICELL INC.: KEY EXECUTIVES

TABLE 169. OMNICELL INC.: COMPANY SNAPSHOT

TABLE 170. OMNICELL INC.: PRODUCT SEGMENTS

TABLE 171. OMNICELL INC.: PRODUCT PORTFOLIO

TABLE 172. OMNICELL INC.: KEY STRATERGIES

TABLE 173. KAPSAM HEALTH PRODUCTS: KEY EXECUTIVES

TABLE 174. KAPSAM HEALTH PRODUCTS: COMPANY SNAPSHOT

TABLE 175. KAPSAM HEALTH PRODUCTS: PRODUCT SEGMENTS

TABLE 176. KAPSAM HEALTH PRODUCTS: PRODUCT PORTFOLIO

TABLE 177. LOCCIONI: KEY EXECUTIVES

TABLE 178. LOCCIONI: COMPANY SNAPSHOT

TABLE 179. LOCCIONI: PRODUCT SEGMENTS

TABLE 180. LOCCIONI: PRODUCT PORTFOLIO

## List Of Figures

### LIST OF FIGURES

FIGURE 01. COMPOUNDING CHEMOTHERAPY MARKET, 2024-2034

FIGURE 02. SEGMENTATION OF COMPOUNDING CHEMOTHERAPY MARKET, 2024-2034

FIGURE 03. TOP IMPACTING FACTORS IN COMPOUNDING CHEMOTHERAPY MARKET (2024 TO 2034)

FIGURE 04. TOP INVESTMENT POCKETS IN COMPOUNDING CHEMOTHERAPY MARKET (2025-2034)

FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 06. MODERATE THREAT OF NEW ENTRANTS

FIGURE 07. MODERATE THREAT OF SUBSTITUTES

FIGURE 08. MODERATE INTENSITY OF RIVALRY

FIGURE 09. LOW BARGAINING POWER OF BUYERS

FIGURE 10. GLOBAL COMPOUNDING CHEMOTHERAPY MARKET: DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 11. COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE TYPE, 2024 AND 2034(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF COMPOUNDING CHEMOTHERAPY MARKET FOR CHEMOTHERAPEUTIC, BY COUNTRY 2024 AND 2034(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF COMPOUNDING CHEMOTHERAPY MARKET FOR NON-CHEMOTHERAPEUTIC, BY COUNTRY 2024 AND 2034(%)

FIGURE 14. COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE, 2024 AND 2034(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF COMPOUNDING CHEMOTHERAPY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY 2024 AND 2034(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF COMPOUNDING CHEMOTHERAPY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY 2024 AND 2034(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF COMPOUNDING CHEMOTHERAPY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY 2024 AND 2034(%)

FIGURE 18. COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD, 2024 AND 2034(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF COMPOUNDING

CHEMOTHERAPY MARKET FOR GRAVIMETRIC AUTOMATED COMPOUNDING DEVICE, BY COUNTRY 2024 AND 2034(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF COMPOUNDING CHEMOTHERAPY MARKET FOR VOLUMETRIC AUTOMATED COMPOUNDING DEVICE, BY COUNTRY 2024 AND 2034(%)

FIGURE 21. COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY, 2024 AND 2034(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF COMPOUNDING CHEMOTHERAPY MARKET FOR STERILE, BY COUNTRY 2024 AND 2034(%)

FIGURE 23. COMPARATIVE SHARE ANALYSIS OF COMPOUNDING CHEMOTHERAPY MARKET FOR NON-STERILE, BY COUNTRY 2024 AND 2034(%)

FIGURE 24. COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY, 2024 AND 2034(%)

FIGURE 25. COMPARATIVE SHARE ANALYSIS OF COMPOUNDING CHEMOTHERAPY MARKET FOR WITH ROBOTIC ARM, BY COUNTRY 2024 AND 2034(%)

FIGURE 26. COMPARATIVE SHARE ANALYSIS OF COMPOUNDING CHEMOTHERAPY MARKET FOR WITHOUT ROBOTIC ARM, BY COUNTRY 2024 AND 2034(%)

FIGURE 27. COMPOUNDING CHEMOTHERAPY MARKET BY REGION, 2024 AND 2034(%)

FIGURE 28. U.S. COMPOUNDING CHEMOTHERAPY MARKET, 2024-2034 (\$MILLION)

FIGURE 29. CANADA COMPOUNDING CHEMOTHERAPY MARKET, 2024-2034 (\$MILLION)

FIGURE 30. MEXICO COMPOUNDING CHEMOTHERAPY MARKET, 2024-2034 (\$MILLION)

FIGURE 31. GERMANY COMPOUNDING CHEMOTHERAPY MARKET, 2024-2034 (\$MILLION)

FIGURE 32. FRANCE COMPOUNDING CHEMOTHERAPY MARKET, 2024-2034 (\$MILLION)

FIGURE 33. UK COMPOUNDING CHEMOTHERAPY MARKET, 2024-2034 (\$MILLION)

FIGURE 34. ITALY COMPOUNDING CHEMOTHERAPY MARKET, 2024-2034 (\$MILLION)

FIGURE 35. SPAIN COMPOUNDING CHEMOTHERAPY MARKET, 2024-2034 (\$MILLION)

FIGURE 36. REST OF EUROPE COMPOUNDING CHEMOTHERAPY MARKET, 2024-2034 (\$MILLION)

FIGURE 37. JAPAN COMPOUNDING CHEMOTHERAPY MARKET, 2024-2034  
(\$MILLION)

FIGURE 38. CHINA COMPOUNDING CHEMOTHERAPY MARKET, 2024-2034  
(\$MILLION)

FIGURE 39. INDIA COMPOUNDING CHEMOTHERAPY MARKET, 2024-2034  
(\$MILLION)

FIGURE 40. AUSTRALIA COMPOUNDING CHEMOTHERAPY MARKET, 2024-2034  
(\$MILLION)

FIGURE 41. SOUTH KOREA COMPOUNDING CHEMOTHERAPY MARKET,  
2024-2034 (\$MILLION)

FIGURE 42. REST OF ASIA-PACIFIC COMPOUNDING CHEMOTHERAPY MARKET,  
2024-2034 (\$MILLION)

FIGURE 43. BRAZIL COMPOUNDING CHEMOTHERAPY MARKET, 2024-2034  
(\$MILLION)

FIGURE 44. SAUDI ARABIA COMPOUNDING CHEMOTHERAPY MARKET,  
2024-2034 (\$MILLION)

FIGURE 45. SOUTH AFRICA COMPOUNDING CHEMOTHERAPY MARKET,  
2024-2034 (\$MILLION)

FIGURE 46. REST OF LAMEA COMPOUNDING CHEMOTHERAPY MARKET,  
2024-2034 (\$MILLION)

FIGURE 47. TOP WINNING STRATEGIES, BY YEAR (2021-2024)

FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2024)

FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY (2021-2024)

FIGURE 50. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 51. COMPETITIVE DASHBOARD

FIGURE 52. COMPETITIVE HEATMAP: COMPOUNDING CHEMOTHERAPY  
MARKET

FIGURE 53. TOP PLAYER POSITIONING, 2024

FIGURE 54. ATS CORPORATION: NET REVENUE, 2022-2024 (\$MILLION)

FIGURE 55. ATS CORPORATION: REVENUE SHARE BY REGION, 2024 (%)

FIGURE 56. GRIFOLS, S.A.: NET REVENUE, 2022-2024 (\$MILLION)

FIGURE 57. GRIFOLS, S.A.: REVENUE SHARE BY SEGMENT, 2024 (%)

FIGURE 58. GRIFOLS, S.A.: REVENUE SHARE BY REGION, 2024 (%)

FIGURE 59. OMNICELL INC.: NET REVENUE, 2022-2024 (\$MILLION)

FIGURE 60. OMNICELL INC.: REVENUE SHARE BY REGION, 2024 (%)

## I would like to order

Product name: Compounding Chemotherapy Market By Dose type (Chemotherapeutic, Non-chemotherapeutic), By Compounding Type (Pharmaceutical Ingredient Alteration, Currently Unavailable Pharmaceutical Manufacturing, Pharmaceutical Dosage Alteration), By Delivery method (Gravimetric automated Compounding Device, Volumetric Automated Compounding Device), By Sterility (Sterile, Non-sterile), By Technology (With Robotic arm, Without Robotic Arm): Global Opportunity Analysis and Industry Forecast, 2025-2034

Product link: <https://marketpublishers.com/r/C26263A8F3A6EN.html>

Price: US\$ 2,655.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C26263A8F3A6EN.html>